Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P04637 (
p53
)
77,613
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We determined the molecular mechanisms by which trichostatin A (TSA) induced insulin-like growth factor-binding protein 3 (IGFBP-3) gene expression in Hep3B cells, a
p53
-mutant human hepatocellular carcinoma (HCC) cell line. TSA induced the expressions of the IGFBP-3 mRNA and protein and the activation of its promoter. Using IGFBP-3 promoter deletion constructs, the TSA-responsive element was mapped to a region between -115 and -30, relative to the transcription start site. Promoter mutation analysis confirmed that the TSA-responsive element coincides with the
Sp1
/GC-rich region on the IGFBP-3 promoter. This transcriptional activation appears to be mediated by both the
Sp1
and Sp3 transcription factors and, in particular, by the phosphorylation of
Sp1
, because treatment of Hep3B cells and Schneider (SL2) cells with TSA significantly activated phosphorylation of
Sp1
in a dose-dependent manner. Consistent with the transcriptional activation of the IGFBP-3 promoter by TSA, TSA treatment led to the release of HDAC1 and Sp3 from the
Sp1
transcriptional factor complex, indicating the involvement of multiprotein complexes containing
Sp1
, Sp3, p300, and HDAC-1 in IGFBP-3 activation by TSA. Taken together, these results show that
Sp1
phosphorylation and the modulation of the
Sp1
/Sp3/HDAC1 multiprotein complex play a pivotal role in the transcriptional activation of the IGFBP-3 promoter through the
Sp1
/GC-rich site by TSA.
...
PMID:Trichostatin A, a histone deacetylase inhibitor, activates the IGFBP-3 promoter by upregulating Sp1 activity in hepatoma cells: alteration of the Sp1/Sp3/HDAC1 multiprotein complex. 1220 Jan 49
Tumor suppressor p53
induces the cellular response to DNA damage mainly by regulating expression of its downstream target genes. The human securin is an anaphase inhibitor, preventing premature chromosome separation through inhibition of separase activity. It is also known as the product of the human pituitary tumor-transforming gene, pttg, a proto-oncogene. Here we report that the expression of human securin is suppressed in cells treated with the DNA-damaging drugs doxorubicin and bleomycin. This suppression requires functional
p53
. Analysis of the human securin promoter reveals that DNA-binding sites for
Sp1
and NF-Y are both required for activation of securin expression; however, only the NF-Y site is essential for the suppression by
p53
. Our study indicates that securin is a p53 target gene and may play a role in
p53
-mediated cellular response to DNA damage.
...
PMID:DNA damage-induced inhibition of securin expression is mediated by p53. 1240 81
Direct target loci for the transcription factor
p53
were identified through the employment of a combination of a modified version of chromosomal immunoprecipitation and inverse PCR. Irradiation of Hela cells to drive DNA damage response was followed by sequential chromosomal immunoprecipitation utilizing antibodies which recognize the large subunit of RNA polymerase II and
p53
. Inverse PCR with degenerate oligonucleotides specific for the
p53
binding site was subsequently performed on immunoprecipitated DNA and fragments containing putative p53 target genes were subcloned and sequenced. Two sequences were identified which contain near-consensus
p53
binding sites as well as recognition sites for the core transcriptional machinery including RNA polymerase II and
Sp1
. Cotransfections of vectors containing these sequences linked to a reporter with
p53
expression vectors resulted in stimulation of transcription. Application of the technology described herein may result in the identification of target loci for a wide variety of transcription factors.
...
PMID:[Identification of two new p53 target genes through implementation of the modified chromatin immunoprecipitation method and inverse PCR]. 1250 May 42
In response to changes in the external environment cells must initiate a coordinated program of gene expression for them to adapt. IEX-1 (immediate early response gene X-1) is precisely regulated by multiple transcription factors among which
p53
, NF-kappaB/rel,
Sp1
and c-Myc play central roles, to ensure rapid and transient expression of IEX-1 in cells under a variety of stress conditions. Overexpression of IEX-1 renders some cells sensitive to apoptosis and accelerates cell cycle progression, but reduces proliferation of other cells, whereas disruption of IEX-1 expression is associated with decreases in both apoptosis and cell cycle progression. In sharp contrast to in vitro studies, in vivo constitutive expression of IEX-1 prevents activated T cells but not B cells from apoptosis, as shown using IEX-1-transgenic mice that target IEX-1 expression specifically to lymphocytes driven by the Emu enhancer. The animals developed a lupus-like disease and subsequently a high incidence of T cell lymphomas when they aged, due to insufficient apoptosis of T cells. These varied effects of IEX-1 on cell death and cell cycle progression in a cell-context dependent fashion implicate that IEX-1 is involved in more than one signaling pathway, understanding of which will certainly improve our knowledge with respect to cancer biology, cell death and cell cycle regulation.
...
PMID:Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis. 1251 Jan 47
Lung tumors from AC3F1 mice treated with aflatoxin B(1) (AFB(1)), were examined for loss of alleles, point mutations and hypermethylation of CpG sites within the promoters of the two genes in the Ink4a/Arf gene locus. Loss of microsatellite alleles in the Ink4a/Arf region occurred in 22 of 74 (30%) AFB(1)-induced lung tumors. Fifty-one of 61 (83%) tumors had at least partial methylation of CpG sites within the p16Ink4a promoter-exon 1alpha region. At least partial methylation of CpG sites was observed in 43 of 49 (88%) tumors analyzed for p19Arf promoter hypermethylation, with methylation of identified transcription factor binding sites or consensus sequences occurring in 21 tumors (DMP1/Ets in two tumors, CTCF in four tumors, E2F in three tumors,
Sp1
in 16 tumors). Two tumors contained point mutations in the p19Arf promoter. Nuclear staining for p19(Arf) was decreased by 80-100% in 41 of 71 (58%) tumors. The concordance between p19Arf molecular perturbations and altered protein expression was 63%. However, upon comparing p19Arf promoter perturbations (i.e. methylation of functional transcription factor binding sites and point mutations) and altered p19(Arf) expression, the concordance was 86%, suggesting a mechanism for changes in protein expression in some tumors. There was an absence of a mutually exclusive relationship between disruption of
p53
and p19(Arf), since the concordance was 62%. Similarly, no evidence was found of inverse relationships between perturbation of p16Ink4a and p19(Arf) (43% concordance) or p16Ink4(a) and
p53
(37% concordance), suggesting that inactivation of these genes occurs independently and provides evidence that, although these genes may participate in cooperative cellular pathways, they also have functions in independent pathways that are important in mouse lung tumorigenesis.
...
PMID:Perturbations of the Ink4a/Arf gene locus in aflatoxin B1-induced mouse lung tumors. 1253 57
Progestins are frequently used in the treatment of advanced breast and endometrial cancer. The human breast carcinoma cell line T47D shows a biphasic response to progestins. Short-term progestin treatment leads to enhanced DNA synthesis, while this line is growth inhibited upon prolonged exposure. An important protein involved in growth regulation by progestins in this cell is the CDK inhibitor p21(Cip1,Waf1). We show that after 1 day of progestin treatment in T47D cells, the p21 promoter-proximal region containing
Sp1
binding sites is crucial in the induction by progestins. However, after 3 days the activity of the promoter-distal region becomes predominant in T47D cells or the endometrial carcinoma cell line ECC1. This is dependent upon two domains within this region that contain
p53
response elements. In ECC1 and T47D cells 3-day progestin treatment induces a reporter containing a
p53
response element, but not a mutated version. This induction is due to activation of
p53
by progestin, which may be caused by nuclear translocation of
p53
. These data indicate that upon prolonged exposure, progestins activate
p53
, in human breast and endometrial tumor cells, which up-regulates the p21(Cip1,Waf1) promoter. This may be an important mechanism involved in progestin-inhibited cellular proliferation in these cells.
...
PMID:Prolonged progestin treatment induces the promoter of CDK inhibitor p21 Cip1,Waf1 through activation of p53 in human breast and endometrial tumor cells. 1265 Nov 58
The cyclin-dependent kinase inhibitor p21/WAF1/CIP1 is an important regulator of cell cycle progression, senescence, and differentiation. Genotoxic stress leads to activation of the
tumor suppressor p53
and subsequently to induction of p21 expression. Here we show that the
tumor suppressor p53
cooperates with the transcription factor Sp1 in the activation of the p21 promoter, whereas histone deacetylase 1 (HDAC1) counteracts
p53
-induced transcription from the p21 gene. The
p53 protein
binds directly to the C terminus of
Sp1
, a domain which was previously shown to be required for the interaction with HDAC1. Induction of
p53
in response to DNA-damaging agents resulted in the formation of
p53
-
Sp1
complexes and simultaneous dissociation of HDAC1 from the C terminus of
Sp1
. Chromatin immunoprecipitation experiments demonstrated the association of HDAC1 with the p21 gene in proliferating cells. Genotoxic stress led to recruitment of
p53
, reduced binding of HDAC1, and hyperacetylation of core histones at the p21 promoter. Our findings show that the deacetylase HDAC1 acts as an antagonist of the
tumor suppressor p53
in the regulation of the cyclin-dependent kinase inhibitor p21 and provide a basis for understanding the function of histone deacetylase inhibitors as antitumor drugs.
...
PMID:The tumor suppressor p53 and histone deacetylase 1 are antagonistic regulators of the cyclin-dependent kinase inhibitor p21/WAF1/CIP1 gene. 1266 70
Transcription involves molecular interactions between general and regulatory transcription factors with further regulation by protein-protein interactions (e.g. transcriptional cofactors). Here we describe functional interaction between DNA-binding transcription factor and histone chaperone. Affinity purification of factors interacting with the DNA-binding domain of the transcription factor Sp1 showed
Sp1
to interact with the histone chaperone TAF-I, both alpha and beta isoforms. This interaction was specific as
Sp1
did not interact with another histone chaperone CIA nor did other tested DNA-binding regulatory factors (MyoD, NFkappaB,
p53
) interact with TAF-I. Interaction of
Sp1
and TAF-I occurs both in vitro and in vivo. Interaction with TAF-I results in inhibition of DNA-binding, and also likely as a result of such, inhibition of promoter activation by
Sp1
. Collectively, we describe interaction between DNA-binding transcription factor and histone chaperone which results in negative regulation of the former. This novel regulatory interaction advances our understanding of the mechanisms of eukaryotic transcription through DNA-binding regulatory transcription factors by protein-protein interactions, and also shows the DNA-binding domain to mediate important regulatory interactions.
...
PMID:Functional interaction of the DNA-binding transcription factor Sp1 through its DNA-binding domain with the histone chaperone TAF-I. 1275 64
DNA methylation in the promoter of certain genes is associated with transcriptional silencing. Methylation affects gene expression directly by interfering with transcription factor binding and/or indirectly by recruiting histone deacetylases through methyl-DNA-binding proteins. In this study, we demonstrate that the human lung cancer cell line H719 lacks
p53
-dependent and -independent p21(Cip1) expression.
p53
response to treatment with gamma irradiation or etoposide is lost due to a mutation at codon 242 of
p53
(C-->W). Treatment with depsipeptide, an inhibitor of histone deacetylase, was unable to induce
p53
-independent p21(Cip1) expression because the promoter of p21(Cip1) in these cells is hypermethylated. By analyzing luciferase activity of transfected p21(Cip1) promoter vectors, we demonstrate that depsipeptide functions on
Sp1
-binding sites to induce p21(Cip1) expression. We hypothesize that hypermethylation may interfere with
Sp1
/Sp3 binding. By using an electrophoretic mobility shift assay, we show that, although methylation within the consensus
Sp1
-binding site did not reduce
Sp1
/Sp3 binding, methylation outside of the consensus
Sp1
element induced a significant decrease in
Sp1
/Sp3 binding. Depsipeptide induced p21(Cip1) expression was reconstituted when cells were pretreated with 5-aza-2'-deoxycytidine. Our data suggest, for the first time, that hypermethylation around the consensus
Sp1
-binding sites may directly reduce
Sp1
/Sp3 binding, therefore leading to a reduced p21(Cip1) expression in response to depsipeptide treatment.
...
PMID:Methylation of adjacent CpG sites affects Sp1/Sp3 binding and activity in the p21(Cip1) promoter. 1277 51
Phospholipase D (PLD) is known to stimulate cell cycle progression and to transform murine fibroblast cells into tumorigenic forms, although the precise mechanisms are not elucidated. In this report, we demonstrated that both PLD1 and PLD2 repressed expression of cyclin-dependent kinase inhibitor p21 gene in an additive manner. The phospholipase activity of PLDs was important for the effect. PLD1 repressed the p21 promoter by decreasing the level of
p53
, whereas PLD2 via a
p53
-independent pathway through modulating
Sp1
activity. Taken together, we suggest that PLD isozymes stimulate cell growth by repressing expression of p21 gene, which may ultimately lead to carcinogenesis.
...
PMID:Transcriptional repression of cyclin-dependent kinase inhibitor p21 gene by phospholipase D1 and D2. 1278 87
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>